Vaccinex Inc Financials
Vaccinex Inc (VCNX) reported $601K in revenue for fiscal year 2024, up 5.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Vaccinex still operates like a funded research platform, with external capital carrying a cost base that revenue does not support.
From FY2021 to FY2024, R&D expense fell from$17.2M to$12.5M . Even after that cut, cash ended FY2024 at just$1.1M and the current ratio slipped below 1x, showing that lower research spend has not changed the core mechanic: the business still depends on outside funding because sales do not finance operations.
FY2024 revenue was only
Balance-sheet pressure is concentrated in the near term: current liabilities were
Financial Health Signals
Vaccinex Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Vaccinex Inc generated $601K in revenue in fiscal year 2024. This represents an increase of 5.4% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Vaccinex Inc held $1.1M in cash against $0 in long-term debt as of fiscal year 2024, with $5.1M of liabilities due within a year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
None of these metrics is reported for fiscal year 2024.
Capital Allocation
Vaccinex Inc invested $12.5M in research and development in fiscal year 2024. This represents a decrease of 24.3% from the prior year.
Vaccinex Inc invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.2% from the prior year.
Not reported for fiscal year 2024.
VCNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $601K+5.4% | $570K+107.3% | $275K-69.4% | $900K+44.0% | $625K+19.5% | $523K-27.8% | $724K+704.4% | $90K |
| Cost of Revenue | N/A | N/A | N/A | N/A | $2K-99.0% | $199K-80.7% | $1.0M+545.6% | $160K |
| Gross Profit | N/A | N/A | N/A | N/A | $623K+92.3% | $324K+204.9% | -$309K-341.4% | -$70K |
| R&D Expenses | $12.5M-24.3% | $16.6M+18.6% | $14.0M-18.5% | $17.2M-20.4% | $21.5M | N/A | $22.4M+35.1% | $16.6M |
| SG&A Expenses | $6.8M-1.3% | $6.9M+10.9% | $6.2M-0.4% | $6.2M-15.9% | $7.4M+11.0% | $6.7M+44.4% | $4.6M+3.0% | $4.5M |
| Operating Income | N/A | N/A | -$19.9M+11.5% | -$22.5M+20.6% | -$28.3M | N/A | -$27.3M-29.3% | -$21.1M |
| Interest Expense | $2K+100.0% | $1K-50.0% | $2K-99.8% | $809K+65.4% | $489K | N/A | $392K-71.1% | $1.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | N/A | -$19.8M+11.5% | -$22.4M+22.4% | -$28.9M | N/A | -$29.5M-57.7% | -$18.7M |
| EPS (Diluted) | -$8.88 | -$43.68 | -$98.05 | -$0.78 | N/A | N/A | N/A | N/A |
VCNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M-28.5% | $3.6M-54.5% | $8.0M-19.0% | $9.8M-15.9% | $11.7M+154.2% | $4.6M-79.1% | $22.0M+295.1% | $5.6M |
| Current Assets | $2.5M-24.4% | $3.3M-55.2% | $7.5M-20.5% | $9.4M-16.7% | $11.3M+181.4% | $4.0M-81.3% | $21.4M+330.7% | $5.0M |
| Cash & Equivalents | $1.1M-27.9% | $1.5M-76.0% | $6.4M-25.6% | $8.6M-18.9% | $10.6M+281.7% | $2.8M-50.6% | $5.6M+34.4% | $4.2M |
| Accounts Receivable | $838K-12.8% | $961K+449.1% | $175K | N/A | $157K-82.5% | $898K+40.5% | $639K+446.2% | $117K |
| Total Liabilities | $5.1M-14.4% | $5.9M+113.4% | $2.8M+14.5% | $2.4M-93.6% | $38.3M+24.1% | $30.8M+0.6% | $30.6M-76.6% | $131.0M |
| Current Liabilities | $5.1M-14.1% | $5.9M+133.2% | $2.5M+12.5% | $2.3M-82.9% | $13.2M+91.6% | $6.9M+2.9% | $6.7M+60.5% | $4.2M |
| Long-Term Debt | $0-100.0% | $26K-74.3% | $101K-42.3% | $175K-84.6% | $1.1M | N/A | N/A | N/A |
| Total Equity | -$2.5M-7.7% | -$2.3M-144.5% | $5.2M-29.9% | $7.4M+127.9% | -$26.6M-1.3% | -$26.2M-204.3% | -$8.6M+93.1% | -$125.5M |
| Retained Earnings | -$358.6M-5.5% | -$339.9M-6.3% | -$319.7M-6.6% | -$299.9M-8.1% | -$277.5M-11.6% | -$248.6M-14.7% | -$216.8M-15.8% | -$187.2M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
VCNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$19.1M+24.6% | -$25.3M+11.7% | -$28.6M | N/A | -$25.3M-18.2% | -$21.4M |
| Capital Expenditures | $22K-67.2% | $67K-32.3% | $99K+209.4% | $32K-89.0% | $290K+271.8% | $78K-66.8% | $235K+245.6% | $68K |
| Free Cash Flow | N/A | N/A | -$19.2M+24.3% | -$25.3M+12.5% | -$28.9M | N/A | -$25.5M-18.9% | -$21.5M |
| Investing Cash Flow | -$22K+67.2% | -$67K+32.3% | -$99K-209.4% | -$32K+89.0% | -$290K-102.1% | $14.1M+198.8% | -$14.2M-20842.6% | -$68K |
| Financing Cash Flow | N/A | $16.6M-2.3% | $17.0M-27.2% | $23.3M-36.5% | $36.8M+166.4% | $13.8M-66.3% | $41.0M+70.8% | $24.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VCNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | 99.7%+37.7pp | 62.0%+104.6pp | -42.7%+35.1pp | -77.8% |
| Operating Margin | N/A | N/A | -7238.5% | -2498.9% | -4533.0% | N/A | -3768.1% | -23448.9% |
| Net Margin | N/A | N/A | -7205.5% | -2486.7% | -4616.2% | N/A | -4077.1% | -20802.2% |
| Return on Equity | N/A | N/A | -381.6%-79.6pp | -301.9% | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | -248.4%-21.0pp | -227.4%+19.2pp | -246.6% | N/A | -134.0%+201.8pp | -335.8% |
| Current Ratio | 0.50-0.1x | 0.57-2.4x | 2.95-1.2x | 4.17+3.3x | 0.86+0.3x | 0.58-2.6x | 3.20+2.0x | 1.19 |
| Debt-to-Equity | N/A | N/A | 0.020.0x | 0.02 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | -6972.0% | -2814.4% | -4629.9% | N/A | -3523.6% | -23838.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Vaccinex Inc Ranks
Frequently Asked Questions
What is Vaccinex Inc's annual revenue?
Vaccinex Inc (VCNX) reported $601K in total revenue for fiscal year 2024. This represents a 5.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vaccinex Inc's revenue growing?
Vaccinex Inc (VCNX) revenue grew by 5.4% year-over-year, from $570K to $601K in fiscal year 2024.
How much debt does Vaccinex Inc have?
As of fiscal year 2024, Vaccinex Inc (VCNX) had $1.1M in cash and equivalents against $0 in long-term debt.
What are Vaccinex Inc's total assets?
Vaccinex Inc (VCNX) had $2.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Vaccinex Inc's capital expenditures?
Vaccinex Inc (VCNX) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Vaccinex Inc spend on research and development?
Vaccinex Inc (VCNX) invested $12.5M in research and development during fiscal year 2024.
What is Vaccinex Inc's current ratio?
Vaccinex Inc (VCNX) had a current ratio of 0.50 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is Vaccinex Inc's debt-to-equity ratio negative or not reported?
Vaccinex Inc (VCNX) has negative shareholder equity of -$2.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.